Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

医学 伊立替康 替莫唑胺 肉瘤 外科 内科学 临床研究阶段 化疗 癌症 结直肠癌 病理
作者
Lars M. Wagner,Nancy McAllister,Robert E. Goldsby,Aaron R. Rausen,Rene Y. McNall‐Knapp,M. Beth McCarville,Karen H. Albritton
出处
期刊:Pediatric Blood & Cancer [Wiley]
卷期号:48 (2): 132-139 被引量:196
标识
DOI:10.1002/pbc.20697
摘要

BACKGROUND: Preclinical models show sequence-dependent synergy with the combination of temozolomide and irinotecan, and a Phase I trial has demonstrated the combination to be tolerable and active in children with relapsed solid tumors. Because responses were seen in patients with Ewing sarcoma (ES) on that trial, additional patients were treated with this combination following study completion. PROCEDURE: We reviewed data from all ES patients treated with temozolomide and irinotecan at four institutions, including seven patients treated on the above Phase I trial. RESULTS: Sixteen patients received a total of 95 courses, with a median of five courses per patient. All patients had either progressive disease (PD) during initial therapy (n = 5) or relapse within 2 years of diagnosis (n = 11). Twelve patients had metastatic disease at diagnosis, including 5 with bone and/or marrow metastases. Patients received oral temozolomide 100 mg/m(2)/day on days 1-5 plus intravenous irinotecan 10-20 mg/m(2)/day on days 1-5 and 8-12, with courses repeated every 21-28 days. We observed 1 complete, 3 partial, and 3 minor responses in 14 evaluable patients, with a median duration of response of 30 weeks. Planned 21-day courses were tolerable and no more toxic than 28-day courses. Myelosuppression was minimal despite heavy pretreatment. Grade 3-4 diarrhea occurred in 11% of courses and was related to higher irinotecan doses. Over 600 irinotecan doses were administered uneventfully at home. CONCLUSIONS: Temozolomide and protracted intravenous irinotecan given in 21-day courses was tolerable and active in patients with advanced ES. Home administration of irinotecan with temozolomide was safe and is reasonable palliative therapy. A formal Phase II study using a uniform dose and schedule is warranted to better define activity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被padapada采纳,获得10
2秒前
木子完成签到,获得积分10
2秒前
Superman完成签到,获得积分10
3秒前
佳佳发布了新的文献求助10
3秒前
W43完成签到,获得积分10
4秒前
Xuuuu完成签到 ,获得积分10
4秒前
chenyi完成签到 ,获得积分10
4秒前
4秒前
健康的谷芹完成签到,获得积分10
4秒前
4秒前
czn0523完成签到 ,获得积分10
6秒前
Criminology34举报听雨的求助涉嫌违规
7秒前
8秒前
自由无敌完成签到,获得积分10
8秒前
fdawn完成签到,获得积分10
9秒前
9秒前
7ian完成签到 ,获得积分10
10秒前
李健的应助被Lin采纳,获得10
10秒前
gyro发布了新的文献求助10
10秒前
LL发布了新的文献求助10
10秒前
烟花的应助被浪迹采纳,获得10
11秒前
gentille完成签到,获得积分10
11秒前
彤503关注了科研通微信公众号
12秒前
12秒前
caleb完成签到,获得积分10
13秒前
null的应助被吃皮采纳,获得10
13秒前
清秀芝麻发布了新的文献求助10
14秒前
Youth完成签到,获得积分10
15秒前
16秒前
我是老大的应助被gyro采纳,获得10
17秒前
mxczsl完成签到,获得积分10
17秒前
17秒前
陈1完成签到 ,获得积分10
17秒前
17秒前
忧虑的凌雪完成签到,获得积分10
18秒前
胡萝贝完成签到,获得积分10
19秒前
19秒前
Sean完成签到,获得积分10
19秒前
雪碧和果冻完成签到,获得积分10
20秒前
MM完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211